![]() Herein, we report the incidence, anatomic distribution, and clinical significance of incidental findings found on 684 consecutive mp-MRI studies performed in a series of 580 patients for the evaluation of prostate cancer at a single center. ![]() However, there are no previous studies comprehensively evaluating and reporting IFs found on mp-MRI done for evaluation of PCa. Previous studies have elicited the costs of IFs in various imaging modalities. However, there is also the risk of patient anxiety, increased cost burden, and iatrogenic morbidity due to work up prompted by IFs that are not clinically significant, potentially leading to an increased public health burden. This has the potential benefit of improving PCa staging through evaluation of the seminal vesicles, bones, and regional pelvic lymph nodes for potential PCa involvement. In addition to the prostate gland, mp-MRI performed for evaluation of prostate cancer can also identify possible pathologies in the field of view: abdominal and pelvic organs, bones, and vasculature. Īs with all imaging modalities, MRI has the potential for revealing both clinically significant and indolent incidental findings (IFs). This ultimately allows for more accurate detection, localization, staging, risk stratification, and treatment counseling for men with PCa. This technology allows for image-guided targeting of cancer suspicious lesions with proven improvement in detection of PCa, particularly clinically significant cancer foci, compared to random TRUS guided biopsy. The use of multiparametric magnetic resonance imaging (mp-MRI) and MRI/US fusion-guided prostate biopsy is gaining traction at many centers. However, this traditional approach can result in high rates of false negative results, undergrading, or understaging of the disease, especially with cancer located in occult regions of the gland: distal apical, midline, subcapsular, and anterior areas. Currently, PCa is commonly diagnosed using systematic transrectal ultrasound (TRUS)-guided prostate biopsies, usually prompted by elevated serum prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) findings. Since multiple management options exist for early staged PCa, early detection with proper risk stratification is critical for selecting the most appropriate treatment options. ![]() Prostate cancer (PCa) is the most common solid-organ malignancy diagnosed in American men, estimated at 161,360 new cases diagnosed in the United States in 2017.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |